Vaporized mebufotenin leads to improvement in treatment‐resistant depression
The Brown University Psychopharmacology Update June 28, 2026 DOI: 10.1002/pu.31471 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant depression |
| Duration | 7-day study |
| Topics | Anxiety Depression |
| Keywords | Depression economics Adverse effect Dosing Regimen Clinical trial Depressive symptoms Placebo response Alkaloids |
| Key findings | An individualized one-day dosing regimen of vaporized 5-MeO-DMT was more effective than placebo in improving depressive symptoms. |
Abstract
An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published online March 2, 2026 in JAMA Psychiatry .